Condition: Breast Cancer · Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Sponsor: Adrienne G. Waks
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant
This description comes directly from the study's public registry record.
Adrienne G Waks, MD · 617-632-3800 · Adrienne_waks@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital Cancer Center | Boston, Massachusetts, United States | Withdrawn |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institite | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05608252